| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
63,980,000 |
| Market
Cap: |
705.70(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$7.68 - $11.25 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 923 |
| Guru Rank Value : 1 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Theravance Biopharma is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicine medicines. Co.'s program include: YUPELRI™ (revefenacin) inhalation solution, nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease; and Lung-selective, Nebulized Pan-Janus Kinase (JAK) Inhibitor (Nezulcitinib), a lung-selective, nebulized JAK inhibitor, in clinical development for the potential treatment of hospitalized patients with acute lung injury caused by Coronavirus Disease 2019.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
999,800 |
2,498,924 |
| Total Buy Value |
$0 |
$0 |
$7,798,440 |
$20,915,775 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
2 |
| Total Shares Sold |
28,000 |
32,000 |
40,000 |
56,529 |
| Total Sell Value |
$300,000 |
$336,000 |
$408,000 |
$568,584 |
| Total People Sold |
1 |
1 |
1 |
2 |
| Total Sell Transactions |
2 |
3 |
5 |
13 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Winningham Rick E |
CHIEF EXECUTIVE OFFICER |
• • – |
2025-06-23 |
4 |
GD |
$0.00 |
$0 |
D/D |
20,000 |
1,733,180 |
|
- |
|
| Winningham Rick E |
CHIEF EXECUTIVE OFFICER |
• • – |
2025-06-13 |
4 |
GA |
$0.00 |
$0 |
I/I |
9,600 |
13,500 |
|
- |
|
| Winningham Rick E |
CHIEF EXECUTIVE OFFICER |
• • – |
2025-06-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
9,600 |
1,753,180 |
|
- |
|
| Farnum Rhonda |
SVP, COMM & MEDICAL AFFAIRS |
• – – |
2025-06-02 |
4 |
S |
$11.00 |
$264,000 |
D/D |
(24,000) |
336,918 |
|
-1% |
|
| Winningham Rick E |
CHIEF EXECUTIVE OFFICER |
• • – |
2025-05-20 |
4 |
D |
$9.45 |
$145,190 |
D/D |
(15,364) |
1,762,780 |
|
- |
|
| Sawaf Aziz |
SVP & CHIEF FINANCIAL OFFICER |
• – – |
2025-05-20 |
4 |
D |
$9.45 |
$88,339 |
D/D |
(9,348) |
364,790 |
|
- |
|
| Grimaud Brett A. |
SVP, GEN COUNSEL AND SECRETARY |
• – – |
2025-05-20 |
4 |
D |
$9.45 |
$92,071 |
D/D |
(9,743) |
384,068 |
|
- |
|
| Farnum Rhonda |
SVP, COMM & MEDICAL AFFAIRS |
• – – |
2025-05-20 |
4 |
D |
$9.45 |
$86,184 |
D/D |
(9,120) |
360,918 |
|
- |
|
| Miller Aine |
SVP, DEV & HEAD OF IRE OFFICE |
• – – |
2025-05-20 |
4 |
D |
$9.45 |
$91,674 |
D/D |
(9,701) |
214,990 |
|
- |
|
| Oconnor Donal |
|
– • – |
2025-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
10,649 |
74,204 |
|
- |
|
| Gray Susannah |
|
– • – |
2025-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
10,649 |
42,137 |
|
- |
|
| Miller Aine |
SVP, DEV & HEAD OF IRE OFFICE |
• – – |
2025-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
10,430 |
224,691 |
|
- |
|
| Grant Jeremy T |
|
– • – |
2025-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
10,649 |
32,954 |
|
- |
|
| Broshy Eran |
|
– • – |
2025-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
10,649 |
91,204 |
|
- |
|
| Pakianathan Deepika |
|
– • – |
2025-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
10,649 |
58,065 |
|
- |
|
| Mitchell Dean J |
|
– • – |
2025-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
10,649 |
91,204 |
|
- |
|
| Smaldone Alsup Laurie |
|
– • – |
2025-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
10,649 |
74,980 |
|
- |
|
| Farnum Rhonda |
SVP, COMM & MEDICAL AFFAIRS |
• – – |
2025-04-21 |
4 |
S |
$9.00 |
$36,000 |
D/D |
(4,000) |
370,038 |
|
-23% |
|
| Miller Aine |
SVP, DEV & HEAD OF IRE OFFICE |
• – – |
2025-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
214,261 |
|
- |
|
| Farnum Rhonda |
SVP, COMM & MEDICAL AFFAIRS |
• – – |
2025-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
374,038 |
|
- |
|
| Winningham Rick E |
CHIEF EXECUTIVE OFFICER |
• • – |
2025-02-28 |
4 |
A |
$9.35 |
$20,364 |
D/D |
2,178 |
1,778,144 |
|
- |
|
| Sawaf Aziz |
SVP & CHIEF FINANCIAL OFFICER |
• – – |
2025-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
374,138 |
|
- |
|
| Grimaud Brett A. |
SVP, GEN COUNSEL AND SECRETARY |
• – – |
2025-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
393,811 |
|
- |
|
| Winningham Rick E |
CHIEF EXECUTIVE OFFICER |
• • – |
2025-02-20 |
4 |
D |
$9.66 |
$339,346 |
D/D |
(35,129) |
1,775,966 |
|
- |
|
| Miller Aine |
SVP, DEV & HEAD OF IRE OFFICE |
• – – |
2025-02-20 |
4 |
D |
$9.66 |
$109,110 |
D/D |
(11,295) |
139,261 |
|
- |
|
545 Records found
|
|
Page 1 of 22 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.19 (1.69%) 
